Sparfloxacin is a new fluoroquinolone that has a broad antibacterial spectrum against gram-positive and gramnegative bacteria in vitro and in vivo [1] . Compared with the other fluoroquinolones, sparfloxacin exhibits a long halflife, allowing once-daily administration [2] .
There have been many reports concerning the effects of antacids, anti-ulcer agents, and other drugs or foods containing metal cations (e.g., aluminum, magnesium, iron, calcium and zinc) on the absorption of fluoroquinolones in healthy volunteers . Previously, the interaction between the fluoroquinolones such as norfloxacin [7, 17] , ofloxacin [15, 17] , ciprofloxacin [3-6, 9, 10] , lomefloxacin [11, 16] , DR-3355 (levofloxacin) [12] and fleroxacin [14, 18] and cations has been reported. Shimada et al. [19] studied the effect of antacid (dried aluminum hydroxide gel) on sparfloxacin gastrointestinal absorption, and found that it was the least inhibited by interaction with an antacid, compared with other new quinolones. Kanemitsu et al. [20, 21] compared the effect of coadministered ferrous sulfate on the absorption of sparfloxacin and norfloxacin, and found that it was less affected by ferrous sulfate than norfloxacin. The interaction between sparfloxacin and sucralfate has been reported by Zix et al. [22] and Kanberi et al. [23] . However, there are only these reports on the interaction of sparfloxacin and sucralfate, and the interaction of sparfloxacin and sodium ferrous citrate is not reported until now.
In the present study, we describe the effects of sucralfate, magnesium oxide and sodium ferrous citrate on the pharmacokinetics of sparfloxacin. [7, 17] , ofloxacin [15, 17] , ciprofloxacin [3-6, 9, 10], lomefloxacin [11, 16] , DR-3355 (levofloxacin) [12] , fleroxacin [14, 18] , and sparfloxacin [19] [20] [21] [22] [23] is decreased by concomitant administration of metal cation containing drugs. Therefore, the interaction between sparfloxacin and sucralfate can be explained primarily by the inhibition of absorption of sparfloxacin.
Studies on the interaction between sucralfate and fluoroquinolones have been reported by a number of investigators. Kawakami et al. [15] has reported that Cmax and AUC of ofloxacin after co-administration with sucralfate decreased by 70 and 61 % compared with ofloxacin alone, respectively.
Lehto et al. [17] has reported that co-administration of sucralfate with norfloxacin and ofloxacin reduced the relative bioavailability of these fluoroquinolones by 91 and 61%, respectively. Lubowski et al. [14] has reported that the relative bioavailability of fleroxacin given with sucralfate was 76% compared with that of fleroxacin alone. Zix et al. [22] has been reported that co-administration of sucralfate and sparfloxacin leads to a 44% decrease in the relative bioavailability of sparfloxacin. Kamberi et al. [23] has been reported that co-administration of sucralfate and sparfloxacin leads to a 49% decrease in the relative bioavailability of sparfloxacin. In the present study, it decreased to 47.6% in AUC as Polk et al. [6] has been reported that concomitant administration of ferrous sulfate and ciprofloxacin reduced the relative bioavailability of ciprofloxacin by 64%. Shiba et al.
[12] has reported that co-administration of ferrous sulfate and DR-3355 (levofloxacin) reduced the relative bioavailability of DR-3355 by 19%. Lehto et al. [16] has reported that ferrous sulfate reduced the Cmax and the AUG-24 of lomefloxacin by 26 and 13%, respectively. In the present study, it was decreased to 28.2% in AUC as compared with sparfloxacin alone by co-administration of sparfloxacin and sodium ferrous citrate. In the most of previous papers, it has been reported that drugs containing aluminum were generally stronger than other cation containing drugs on the inhibition of absorption of fluoroquinolones.
Also, generally, it is known that the grade of the influence of metal cation has a difference according to the kind of new quinolones [20, 21] .
It has been considered that the proposed mechanism of this interaction of fluoroquinolones and the metal cation containing drugs was chelation between the metal ion and the 4-keto oxygen, 3-carboxyl group of the fluoroquinolone.
Since these groups are required for antibacterial activity, one can anticipate that all of the quinolones will interact with these cations, although there may be differences between the quinolones in the extent of interaction. Mizuki et al. [24] has reported for the relationship between the interaction and the chemical structure on fluoroquinolone derivatives in rat.
On the other hand, decreased gastric acidity may also contribute to reduced the oral bioavailability of fluoroquinolone. It has been reported by Lebsack et al. [13] that ranitidine pretreatment reduced the oral bioavailability of enox- In conclusion, the present results sug-
gest that sparfloxacin and sucralfate should not be administered concurrently.
